<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508778</url>
  </required_header>
  <id_info>
    <org_study_id>CTP08239</org_study_id>
    <nct_id>NCT03508778</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the FluidVision Accommodation Intraocular Lens (AIOL)</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>CLinical Evaluation of the FluidVision AIOL for Accommodation Restoration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PowerVision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PowerVision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of an investigational&#xD;
      IOL in providing a range of vision as compared to a commercially available trifocal IOL in&#xD;
      subjects undergoing cataract extraction and IOL implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon obtaining written informed consent and confirmation of subject eligibility via&#xD;
      preoperative assessments, subjects were randomized in a 1:1 ratio to receive either the&#xD;
      investigational IOL or the commercially available trifocal IOL in both eyes. The second eye&#xD;
      for each subject was implanted after completion of the 1-week follow up for the first&#xD;
      implanted eye. The expected total duration of participation for each subject was up to 14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Corrected Near Visual Acuity (DCNVA) at 100% Contrast - First Implanted Eye</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>Visual acuity was tested at a distance of 40 centimeters with distance correction (plus or minus power) in place.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distance Corrected Intermediate Visual Acuity (DCIVA) at 100% Contrast - First Implanted Eye</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>Visual acuity was tested at a distance of 66 centimeters with distance correction (plus or minus power) in place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance Corrected Near Visual Acuity (DCNVA) at low contrast - First Implanted Eye</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>Visual acuity was tested at a distance of 40 centimeters with distance correction (plus or minus power) in place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes with 20/32 or Better Visual Acuity Between 4 meters and 40 centimeters on the Defocus Curve</measure>
    <time_frame>Month 6 postoperative</time_frame>
    <description>A series of plus and minus lenses were placed over the subject's best distance manifest correction to simulate distances from far to hear.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>FluidVision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanOptix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available trifocal IOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FluidVision AIOL</intervention_name>
    <description>Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject</description>
    <arm_group_label>FluidVision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof IQ PanOptix Trifocal IOL</intervention_name>
    <description>Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject</description>
    <arm_group_label>PanOptix</arm_group_label>
    <other_name>PanOptix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract surgery per investigator's standard practice</description>
    <arm_group_label>FluidVision</arm_group_label>
    <arm_group_label>PanOptix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Require cataract extraction by phacoemulsification;&#xD;
&#xD;
          -  Corrected Distance Visual Acuity (CDVA) worse than 20/40 Snellen, or presence of&#xD;
             visually significant lens opacity;&#xD;
&#xD;
          -  Preoperative or predicted postoperative astigmatism of â‰¤ 1.0 diopter.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of current medications that may affect accommodation or confound study results;&#xD;
&#xD;
          -  Systemic disease that may increase the operative risk or confound results;&#xD;
&#xD;
          -  Ocular conditions or degenerative disorders that may predispose the subject to future&#xD;
             complications;&#xD;
&#xD;
          -  Monocular subjects or significant permanent visual function loss in 1 eye;&#xD;
&#xD;
          -  Previous ocular surgery in either eye that may confound the results or increase the&#xD;
             risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PowerVision Investigative Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular lens</keyword>
  <keyword>Eye surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

